【市場調査レポート】 SERD（選択エストロゲン受容体分解）薬のグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Insights, Forecast to 2028

QYResearchが調査・発行した産業分析レポートです。SERD（選択エストロゲン受容体分解）薬のグローバル市場インサイト・予測（～2028年） / Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Insights, Forecast to 2028 / QY2207E09282資料のイメージです。

• レポートコード：QY2207E09282
• 出版社/出版日：QYResearch / 2022年7月
• レポート形態：英文、PDF、111ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

新型コロナウイルス感染症のパンデミックにより、世界のSERD（選択エストロゲン受容体分解）薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にSERD（選択エストロゲン受容体分解）薬の世界市場のxxx％を占める「RAD1901」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「一次治療」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
中国のSERD（選択エストロゲン受容体分解）薬の市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのSERD（選択エストロゲン受容体分解）薬市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのSERD（選択エストロゲン受容体分解）薬市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

SERD（選択エストロゲン受容体分解）薬のグローバル主要メーカーには、Amneal Pharmaceuticals Inc、AstraZeneca, Plc.、Dr. Reddy's Laboratories、Eli Lilly and Company、G1 Therapeutics, Inc.、Glenmark Pharmaceuticals、HBT Labs, Inc、Hoffmann-La Roche AG、InventisBio、Novartis AG、Radius Health、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Zenopharm LLC.、Zentalis Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

SERD（選択エストロゲン受容体分解）薬市場は、種類と用途によって区分されます。世界のSERD（選択エストロゲン受容体分解）薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他

【用途別セグメント】
一次治療、二次治療

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- SERD（選択エストロゲン受容体分解）薬製品概要
- 種類別市場（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）
- 用途別市場（一次治療、二次治療）
- 調査の目的
・エグゼクティブサマリー
- 世界のSERD（選択エストロゲン受容体分解）薬販売量予測2017-2028
- 世界のSERD（選択エストロゲン受容体分解）薬売上予測2017-2028
- SERD（選択エストロゲン受容体分解）薬の地域別販売量
- SERD（選択エストロゲン受容体分解）薬の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬販売量
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬売上
- 主要メーカー別SERD（選択エストロゲン受容体分解）薬価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（RAD1901、GDC-9545、AZD9833、SAR439859、フェソロデックス、その他）
- SERD（選択エストロゲン受容体分解）薬の種類別販売量
- SERD（選択エストロゲン受容体分解）薬の種類別売上
- SERD（選択エストロゲン受容体分解）薬の種類別価格
・用途別市場規模（一次治療、二次治療）
- SERD（選択エストロゲン受容体分解）薬の用途別販売量
- SERD（選択エストロゲン受容体分解）薬の用途別売上
- SERD（選択エストロゲン受容体分解）薬の用途別価格
・北米市場
- 北米のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパのSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米のSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカのSERD（選択エストロゲン受容体分解）薬市場規模（種類別、用途別）
- 主要国別のSERD（選択エストロゲン受容体分解）薬市場規模（トルコ、サウジアラビア）
・企業情報
Amneal Pharmaceuticals Inc、AstraZeneca, Plc.、Dr. Reddy's Laboratories、Eli Lilly and Company、G1 Therapeutics, Inc.、Glenmark Pharmaceuticals、HBT Labs, Inc、Hoffmann-La Roche AG、InventisBio、Novartis AG、Radius Health、Sanofi S.A.、Teva Pharmaceutical Industries Ltd.、Zenopharm LLC.、Zentalis Pharmaceuticals
・産業チェーン及び販売チャネル分析
- SERD（選択エストロゲン受容体分解）薬の産業チェーン分析
- SERD（選択エストロゲン受容体分解）薬の原材料
- SERD（選択エストロゲン受容体分解）薬の生産プロセス
- SERD（選択エストロゲン受容体分解）薬の販売及びマーケティング
- SERD（選択エストロゲン受容体分解）薬の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- SERD（選択エストロゲン受容体分解）薬の産業動向
- SERD（選択エストロゲン受容体分解）薬のマーケットドライバー
- SERD（選択エストロゲン受容体分解）薬の課題
- SERD（選択エストロゲン受容体分解）薬の阻害要因
・主な調査結果

Market Analysis and Insights: Global SERD (Selective Estrogen Receptor Degrader) Drugs Market
The global SERD (Selective Estrogen Receptor Degrader) Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, RAD1901 accounting for % of the SERD (Selective Estrogen Receptor Degrader) Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While First-Line Treatment segment is altered to an % CAGR throughout this forecast period.
China SERD (Selective Estrogen Receptor Degrader) Drugs market size is valued at US$ million in 2021, while the North America and Europe SERD (Selective Estrogen Receptor Degrader) Drugs are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe SERD (Selective Estrogen Receptor Degrader) Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global SERD (Selective Estrogen Receptor Degrader) Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global SERD (Selective Estrogen Receptor Degrader) Drugs market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global SERD (Selective Estrogen Receptor Degrader) Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global SERD (Selective Estrogen Receptor Degrader) Drugs market.
Global SERD (Selective Estrogen Receptor Degrader) Drugs Scope and Market Size
SERD (Selective Estrogen Receptor Degrader) Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global SERD (Selective Estrogen Receptor Degrader) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
RAD1901
GDC-9545
AZD9833
SAR439859
Faslodex
Others
Segment by Application
First-Line Treatment
Second-Line Treatment
By Company
Amneal Pharmaceuticals Inc
AstraZeneca, Plc.
Dr. Reddy’s Laboratories
Eli Lilly and Company
G1 Therapeutics, Inc.
Glenmark Pharmaceuticals
HBT Labs, Inc
Hoffmann-La Roche AG
InventisBio
Novartis AG
Radius Health
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zenopharm LLC.
Zentalis Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 RAD1901
1.2.3 GDC-9545
1.2.4 AZD9833
1.2.5 SAR439859
1.2.6 Faslodex
1.2.7 Others
1.3 Market by Application
1.3.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 First-Line Treatment
1.3.3 Second-Line Treatment
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Perspective (2017-2028)
2.2 SERD (Selective Estrogen Receptor Degrader) Drugs Growth Trends by Region
2.2.1 SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Region (2017-2022)
2.2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Region (2023-2028)
2.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Dynamics
2.3.1 SERD (Selective Estrogen Receptor Degrader) Drugs Industry Trends
2.3.2 SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
2.3.3 SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
2.3.4 SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue
3.1.1 Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Revenue (2017-2022)
3.1.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Players (2017-2022)
3.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue
3.4 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio
3.4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2021
3.5 SERD (Selective Estrogen Receptor Degrader) Drugs Key Players Head office and Area Served
3.6 Key Players SERD (Selective Estrogen Receptor Degrader) Drugs Product Solution and Service
3.7 Date of Enter into SERD (Selective Estrogen Receptor Degrader) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Type
4.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Type (2017-2022)
4.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2023-2028)
5 SERD (Selective Estrogen Receptor Degrader) Drugs Breakdown Data by Application
5.1 Global SERD (Selective Estrogen Receptor Degrader) Drugs Historic Market Size by Application (2017-2022)
5.2 Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
6.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
6.2.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
6.2.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
6.2.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
6.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
6.3.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
6.3.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
6.3.3 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
6.4 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
6.4.1 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
6.4.2 North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
7.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
7.2.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
7.2.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
7.2.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
7.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
7.3.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
7.3.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
7.3.3 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
7.4 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
7.4.1 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
7.4.2 Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
8.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
8.2.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
8.3.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region
8.4.1 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
9.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
9.2.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
9.2.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
9.2.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
9.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
9.3.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
9.3.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
9.3.3 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
9.4 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
9.4.1 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
9.4.2 Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (2017-2028)
10.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type
10.2.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application
10.3.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country
10.4.1 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Amneal Pharmaceuticals Inc
11.1.1 Amneal Pharmaceuticals Inc Company Details
11.1.2 Amneal Pharmaceuticals Inc Business Overview
11.1.3 Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.1.4 Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.1.5 Amneal Pharmaceuticals Inc Recent Developments
11.2 AstraZeneca, Plc.
11.2.1 AstraZeneca, Plc. Company Details
11.2.2 AstraZeneca, Plc. Business Overview
11.2.3 AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.2.4 AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.2.5 AstraZeneca, Plc. Recent Developments
11.3 Dr. Reddy’s Laboratories
11.3.1 Dr. Reddy’s Laboratories Company Details
11.3.2 Dr. Reddy’s Laboratories Business Overview
11.3.3 Dr. Reddy’s Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.3.4 Dr. Reddy’s Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.3.5 Dr. Reddy’s Laboratories Recent Developments
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Details
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.4.4 Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.4.5 Eli Lilly and Company Recent Developments
11.5 G1 Therapeutics, Inc.
11.5.1 G1 Therapeutics, Inc. Company Details
11.5.2 G1 Therapeutics, Inc. Business Overview
11.5.3 G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.5.4 G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.5.5 G1 Therapeutics, Inc. Recent Developments
11.6 Glenmark Pharmaceuticals
11.6.1 Glenmark Pharmaceuticals Company Details
11.6.2 Glenmark Pharmaceuticals Business Overview
11.6.3 Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.6.4 Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.6.5 Glenmark Pharmaceuticals Recent Developments
11.7 HBT Labs, Inc
11.7.1 HBT Labs, Inc Company Details
11.7.2 HBT Labs, Inc Business Overview
11.7.3 HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.7.4 HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.7.5 HBT Labs, Inc Recent Developments
11.8 Hoffmann-La Roche AG
11.8.1 Hoffmann-La Roche AG Company Details
11.8.2 Hoffmann-La Roche AG Business Overview
11.8.3 Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.8.4 Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.8.5 Hoffmann-La Roche AG Recent Developments
11.9 InventisBio
11.9.1 InventisBio Company Details
11.9.2 InventisBio Business Overview
11.9.3 InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.9.4 InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.9.5 InventisBio Recent Developments
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.10.4 Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.10.5 Novartis AG Recent Developments
11.11 Radius Health
11.11.1 Radius Health Company Details
11.11.2 Radius Health Business Overview
11.11.3 Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.11.4 Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.11.5 Radius Health Recent Developments
11.12 Sanofi S.A.
11.12.1 Sanofi S.A. Company Details
11.12.2 Sanofi S.A. Business Overview
11.12.3 Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.12.4 Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.12.5 Sanofi S.A. Recent Developments
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Teva Pharmaceutical Industries Ltd. Company Details
11.13.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.13.3 Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.13.4 Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.13.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.14 Zenopharm LLC.
11.14.1 Zenopharm LLC. Company Details
11.14.2 Zenopharm LLC. Business Overview
11.14.3 Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.14.4 Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.14.5 Zenopharm LLC. Recent Developments
11.15 Zentalis Pharmaceuticals
11.15.1 Zentalis Pharmaceuticals Company Details
11.15.2 Zentalis Pharmaceuticals Business Overview
11.15.3 Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Introduction
11.15.4 Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
11.15.5 Zentalis Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of RAD1901
Table 3. Key Players of GDC-9545
Table 4. Key Players of AZD9833
Table 5. Key Players of SAR439859
Table 6. Key Players of Faslodex
Table 7. Key Players of Others
Table 8. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 9. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region (2017-2022)
Table 12. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region (2023-2028)
Table 14. SERD (Selective Estrogen Receptor Degrader) Drugs Market Trends
Table 15. SERD (Selective Estrogen Receptor Degrader) Drugs Market Drivers
Table 16. SERD (Selective Estrogen Receptor Degrader) Drugs Market Challenges
Table 17. SERD (Selective Estrogen Receptor Degrader) Drugs Market Restraints
Table 18. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Share by Players (2017-2022)
Table 20. Global Top SERD (Selective Estrogen Receptor Degrader) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs as of 2021)
Table 21. Ranking of Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players SERD (Selective Estrogen Receptor Degrader) Drugs Product Solution and Service
Table 25. Date of Enter into SERD (Selective Estrogen Receptor Degrader) Drugs Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Type (2017-2022)
Table 29. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Market Share by Type (2023-2028)
Table 31. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Share by Application (2017-2022)
Table 33. Global SERD (Selective Estrogen Receptor Degrader) Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global SERD (Selective Estrogen Receptor Degrader) Drugs Revenue Share by Application (2023-2028)
Table 35. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 36. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 37. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 38. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 39. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 40. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 41. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 42. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 43. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 44. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 45. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 46. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 47. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 48. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 49. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 50. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 51. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 52. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 53. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 54. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 55. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 56. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 57. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 58. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 59. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 60. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 61. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 62. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 63. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 64. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 65. Amneal Pharmaceuticals Inc Company Details
Table 66. Amneal Pharmaceuticals Inc Business Overview
Table 67. Amneal Pharmaceuticals Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 68. Amneal Pharmaceuticals Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 69. Amneal Pharmaceuticals Inc Recent Developments
Table 70. AstraZeneca, Plc. Company Details
Table 71. AstraZeneca, Plc. Business Overview
Table 72. AstraZeneca, Plc. SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 73. AstraZeneca, Plc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 74. AstraZeneca, Plc. Recent Developments
Table 75. Dr. Reddy's Laboratories Company Details
Table 76. Dr. Reddy's Laboratories Business Overview
Table 77. Dr. Reddy's Laboratories SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 78. Dr. Reddy's Laboratories Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 79. Dr. Reddy's Laboratories Recent Developments
Table 80. Eli Lilly and Company Company Details
Table 81. Eli Lilly and Company Business Overview
Table 82. Eli Lilly and Company SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 83. Eli Lilly and Company Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 84. Eli Lilly and Company Recent Developments
Table 85. G1 Therapeutics, Inc. Company Details
Table 86. G1 Therapeutics, Inc. Business Overview
Table 87. G1 Therapeutics, Inc. SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 88. G1 Therapeutics, Inc. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 89. G1 Therapeutics, Inc. Recent Developments
Table 90. Glenmark Pharmaceuticals Company Details
Table 91. Glenmark Pharmaceuticals Business Overview
Table 92. Glenmark Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 93. Glenmark Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 94. Glenmark Pharmaceuticals Recent Developments
Table 95. HBT Labs, Inc Company Details
Table 96. HBT Labs, Inc Business Overview
Table 97. HBT Labs, Inc SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 98. HBT Labs, Inc Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 99. HBT Labs, Inc Recent Developments
Table 100. Hoffmann-La Roche AG Company Details
Table 101. Hoffmann-La Roche AG Business Overview
Table 102. Hoffmann-La Roche AG SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 103. Hoffmann-La Roche AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 104. Hoffmann-La Roche AG Recent Developments
Table 105. InventisBio Company Details
Table 106. InventisBio Business Overview
Table 107. InventisBio SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 108. InventisBio Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 109. InventisBio Recent Developments
Table 110. Novartis AG Company Details
Table 111. Novartis AG Business Overview
Table 112. Novartis AG SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 113. Novartis AG Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 114. Novartis AG Recent Developments
Table 115. Radius Health Company Details
Table 116. Radius Health Business Overview
Table 117. Radius Health SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 118. Radius Health Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 119. Radius Health Recent Developments
Table 120. Sanofi S.A. Company Details
Table 121. Sanofi S.A. Business Overview
Table 122. Sanofi S.A. SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 123. Sanofi S.A. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 124. Sanofi S.A. Recent Developments
Table 125. Teva Pharmaceutical Industries Ltd. Company Details
Table 126. Teva Pharmaceutical Industries Ltd. Business Overview
Table 127. Teva Pharmaceutical Industries Ltd. SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 128. Teva Pharmaceutical Industries Ltd. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 129. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 130. Zenopharm LLC. Company Details
Table 131. Zenopharm LLC. Business Overview
Table 132. Zenopharm LLC. SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 133. Zenopharm LLC. Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 134. Zenopharm LLC. Recent Developments
Table 135. Zentalis Pharmaceuticals Company Details
Table 136. Zentalis Pharmaceuticals Business Overview
Table 137. Zentalis Pharmaceuticals SERD (Selective Estrogen Receptor Degrader) Drugs Product
Table 138. Zentalis Pharmaceuticals Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022) & (US$ Million)
Table 139. Zentalis Pharmaceuticals Recent Developments
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
List of Figures
Figure 1. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Type: 2021 VS 2028
Figure 2. RAD1901 Features
Figure 3. GDC-9545 Features
Figure 4. AZD9833 Features
Figure 5. SAR439859 Features
Figure 6. Faslodex Features
Figure 7. Others Features
Figure 8. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Application: 2021 VS 2028
Figure 9. First-Line Treatment Case Studies
Figure 10. Second-Line Treatment Case Studies
Figure 11. SERD (Selective Estrogen Receptor Degrader) Drugs Report Years Considered
Figure 12. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Region: 2021 VS 2028
Figure 15. Global SERD (Selective Estrogen Receptor Degrader) Drugs Market Share by Players in 2021
Figure 16. Global Top SERD (Selective Estrogen Receptor Degrader) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in SERD (Selective Estrogen Receptor Degrader) Drugs as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by SERD (Selective Estrogen Receptor Degrader) Drugs Revenue in 2021
Figure 18. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2017-2028)
Figure 20. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application (2017-2028)
Figure 21. North America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Share by Country (2017-2028)
Figure 22. United States SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2017-2028)
Figure 26. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application (2017-2028)
Figure 27. Europe SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Share by Country (2017-2028)
Figure 28. Germany SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Share by Region (2017-2028)
Figure 38. China SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2017-2028)
Figure 46. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application (2017-2028)
Figure 47. Latin America SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Share by Country (2017-2028)
Figure 48. Mexico SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa SERD (Selective Estrogen Receptor Degrader) Drugs Market Size Share by Country (2017-2028)
Figure 54. Turkey SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE SERD (Selective Estrogen Receptor Degrader) Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Amneal Pharmaceuticals Inc Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 58. AstraZeneca, Plc. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 59. Dr. Reddy's Laboratories Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 60. Eli Lilly and Company Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 61. G1 Therapeutics, Inc. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 62. Glenmark Pharmaceuticals Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 63. HBT Labs, Inc Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 64. Hoffmann-La Roche AG Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 65. InventisBio Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 66. Novartis AG Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 67. Radius Health Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 68. Sanofi S.A. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 69. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 70. Zenopharm LLC. Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 71. Zentalis Pharmaceuticals Revenue Growth Rate in SERD (Selective Estrogen Receptor Degrader) Drugs Business (2017-2022)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

以下、関連資料のご紹介

5HT3受容体拮抗薬のグローバル市場インサイト・予測（～2028年）

Global 5HT3 Receptor Antagonists Market Insights, Forecast to 2028
QY2207E09209 2022年7月 108Pages
新型コロナウイルス感染症のパンデミックにより、世界の5HT3受容体拮抗薬の市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に5HT3受容体拮...

ガンマアミノ酪酸（GABA）受容体アゴニストのグローバル市場インサイト・予測（～2028年）

Global Gamma-aminobutyric Acid (GABA) Receptor Agonist Market Insights, Forecast to 2028
QY2207C3462 2022年7月11日 110Pages
新型コロナウイルス感染症のパンデミックにより、世界のガンマアミノ酪酸（GABA）受容体アゴニストの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、20...

オピオイド受容体アゴニストのグローバル市場インサイト・予測（～2028年）

Global Opioid Receptor Agonist Market Insights, Forecast to 2028
QY2207E10435 2022年7月 117Pages
新型コロナウイルス感染症のパンデミックにより、世界のオピオイド受容体アゴニストの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にオピオイド...

世界の制吐薬市場予測（～2028年）：ドーパミン拮抗薬、5-HT-3受容体拮抗薬、NK1受容体拮抗薬、カンナビノイド受容体拮抗薬

Global Antiemetic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
GIR-22E8734 2022年5月 111Pages
制吐薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
...

5-ヒドロキシトリプタミン受容体アゴニストのグローバル市場インサイト・予測（～2028年）

Global 5-Hydroxytryptamine Receptor Agonist Market Insights, Forecast to 2028
QY2207E09210 2022年7月 112Pages
新型コロナウイルス感染症のパンデミックにより、世界の5-ヒドロキシトリプタミン受容体アゴニストの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、202...

アレルギー治療薬のグローバル市場インサイト・予測（～2028年） Most minor allergy symptoms can be treated with antihistamines, corticosteroids, or decongestants. Market Analysis and Insights: Global Allergy Treatment Drugs Market The global Allergy Treatment Drugs market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % du…
5HT3受容体拮抗薬のグローバル市場インサイト・予測（～2028年） Market Analysis and Insights: Global 5HT3 Receptor Antagonists Market The global 5HT3 Receptor Antagonists market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028. Fully considering the economic change by this health crisis, Dolasetron account…
双極性障害薬＆治療のグローバル市場インサイト・予測（～2028年） Drug therapy is currently the core method of treating bipolar disorder, that is, the use of emotional stabilizers to adjust the patient's mood. Bipolar disorder is complex and difficult to control. The drug effect of emotional stabilizers can help patients to suppress their emotions when they are to…
ムーコル症治療薬のグローバル市場インサイト・予測（～2028年） Mucormycosis is a serious infection and needs to be treated with prescription antifungal medicine, usually amphotericin B, posaconazole, or isavuconazole. These medicines are given through a vein (amphotericin B, posaconazole, isavuconazole) or by mouth (posaconazole, isavuconazole). Market Analysis…
世界の瘢痕治療薬市場予測（～2028年）：クリーム、ジェル、スカーシート、その他 The Scar Treatment Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulation…